Section 3 of 6
Product information and disease description
76 evidence topics · 64 sources
Product description
Phase of product development
Product name, regulatory status, and anticipated FDA action
Regulatory status: Under review; BLA submitted December 2025
Product information
Generic, brand name and therapeutic class of product
Product names in the development update
Drug class and molecular description
Dosage forms and strengths
Investigational formulation concentration in the GALLOP protocol
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Other classification in the Dutch horizon scan
AHFS classification code
No evidence found.
Indication
Investigational indication in the Dutch horizon scan
Pharmacology
Mechanism of action
Pharmacodynamics
Phase 1 pharmacodynamics: duration of suppression and ex vivo assay
Pharmacokinetics
Pharmacokinetics: phase 1 healthy-volunteer study
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Pregnancy and lactation: GALLOP exclusion criterion
Pediatric, renal impairment, and hepatic impairment data
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Imsidolimab
No evidence found.
Effects of Imsidolimab on other drugs
No evidence found.
Dosing and administration
Dosage
Investigational acute-flare doses in GEMINI-1
Administration
Access and distribution
No evidence found.
Co-prescribed/Concomitant therapies
GALLOP: prior and concomitant treatment restrictions
Effect of Imsidolimab on quality measures
No evidence found.
Product comparison
Subcutaneous spesolimab 1-ml formulation: terminated NICE technology appraisal TA1144
Place of product in therapy
Disease description
Definition and etiology
Epidemiology
Incidence of Generalized pustular psoriasis
Prevalence of Generalized pustular psoriasis
United States prevalence
Natural history, survival, and mortality
National Psoriasis Foundation consensus: acuity of flares and causes of death
“GPP is a life-threatening disease that needs to be treated as quickly as possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Acute flares of GPP can be life-threatening, with one-half of patients requiring hospitalization and a mortality rate of approximately 3 deaths per 100 patient years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“most common causes of mortality include sepsis and multiorgan failure. Patients receiving biologics have lower in-hospital mortality than those receiving oral agents or corticosteroids alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality systematic review and meta-analysis
Pathophysiology
Diagnosis
Global Delphi consensus: genetic testing
Clinical presentation - signs and symptoms
Cutaneous symptoms: pain and rash during flare episodes
Constitutional symptoms: fever during flare episodes
Long-term morbidity
France: comorbidities in GPP versus plaque psoriasis and general population cohorts
Burden of Generalized pustular psoriasis
Humanistic burden and health-related quality of life
Health-related quality-of-life systematic review
Malaysia health-related quality of life
Economic burden and healthcare resource utilization
Economic burden systematic review
United States economic burden
“GPP patients experienced significantly higher total healthcare costs compared to matched cohorts (GPP vs plaque psoriasis: cost ratio 1.36, 95% confidence interval (1.22, 1.50); GPP vs control: 5.58 (3.73, 8.36)).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of inpatient visits were 4 times higher in GPP patients and 2 times higher in PPP patients compared to their matched cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“GPP and PPP patients have significant economic burden due to higher direct medical and pharmacy costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States healthcare utilization, flares, and severity
Economic impact of Generalized pustular psoriasis on families
No evidence found.
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
IL-36 receptor inhibitors
TNF inhibitors
Expert recommendations: position of cytokine-targeted biologics other than IL-36 inhibitors
TNF inhibitors described in the treatment recommendations
IL-17 inhibitors
Asia-Pacific consensus: maintenance treatment
IL-23 inhibitors
Asia-Pacific consensus: maintenance treatment
Conventional systemic therapies
Non-biologic systemic agents described in the treatment recommendations
Asia-Pacific consensus: systemic corticosteroids for maintenance
Topical therapies
Topical corticosteroids as maintenance or adjunctive therapy
Phototherapy
Japanese guidelines: acute-phase restriction
Granulocyte and monocyte adsorption apheresis
Japanese guidelines: treatment option
Supportive care
Limitations of current therapies
Summary
A treatment review included 118 publications, of which 19% reported clinical trial results. A separate biologics meta-analysis identified moderate heterogeneity and publication bias as limitations affecting reliability. In a U.S. flare-episode analysis, 122 of 513 episodes (24%) had no dermatologic treatment in the interval encompassing the 30 days before, during, and 30 days after the flare. These findings describe limitations of the evidence base and observed treatment delivery; they do not establish comparative efficacy between imsidolimab and existing therapies.
Biologics systematic review and single-arm meta-analysis
National Psoriasis Foundation consensus: access to approved therapy
“We strongly advocate for timely access to US Food and Drug Administration-approved therapies for GPP because delays can increase the risk of mortality in patients with this rapidly progressing disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Spesolimab is the first US Food and Drug Administration-approved treatment that is highly effective in the treatment of GPP flares in adults.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Timely access to approved therapies is critical to reducing morbidity and mortality in patients presenting with GPP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
National Psoriasis Foundation consensus: diagnostic criteria should not gate treatment
“Skin biopsy is not required for the diagnosis of GPP because histologic features may be nonspecific and it may delay treatment of this life-threatening condition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although GPP phenotype classification criteria from the European Rare and Severe Psoriasis Expert Network and Japanese Dermatological Association are informative for clinical trials, these criteria should not be used to deny or delay treatment in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“in patients presenting with acute GPP, one should not wait to fulfill certain arbitrary definitions of GPP before initiating treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
The imsidolimab phase 3 program evaluated IV treatment of GPP flares and subcutaneous maintenance among initial responders. These studies used placebo comparisons rather than an active comparison with spesolimab. The Asia-Pacific consensus included in this report identifies spesolimab as the preferred biologic for acute flares. An imsidolimab treatment position therefore remains investigational while the BLA is under review. The GALLOP protocol specifies physician supervision and availability of full resuscitation facilities for administration.
Heterogeneity of treatment effect
No evidence found.
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Global Delphi consensus: treatment goals
“Short-term treatment goals should include pustule clearance within 7 days and prevention of pustule recurrence” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“minimizing disease activity through flare prevention” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote